L. Fernando Mendoza’s Post

Here, researchers use high-resolution #cryoEM to determine structures of the CDK-activating kinase, a master regulator of cell growth and division. The study offers detailed insight into inhibitor interactions and networks, and the mechanisms contributing to inhibitor selectivity, thereby providing the basis for rational design of next-generation therapeutics. These results establish a methodological framework for the use of high-resolution cryo-EM in structure-based #DrugDesign.

In this month’s #InnovationCommunity news update, read about Exscientia’s merger with Recursion to transform AI-driven drug discovery. Also this month, Replimune’s RP1 gains Breakthrough Therapy Designation from FDA, Pathios Therapeutics advances innovative cancer immunotherapy with PTT-4256 and Tokamak Energy secures $125M (£98.6M) to advance fusion and magnet technologies. Read all of the latest news and announcements from Milton Park-based companies: https://ow.ly/XfIE50Utvkz Image: ©Recursion/ Exscientia. All rights reserved. #InnovationCommunity #Oxford #IndustryNews #AI #Pharma #LifeSciences #FusionEnergy

#AACR24 Analysis 3: Kelonia Therapeutics and Carisma Therapeutics presented preclinical updates from their programs using innovative #celltherapy platforms. Celltelligence provides insights and key context for selected presentations. The following topics are covered: • Kelonia reported preclinical data from its KLN-1010, an in vivo iGPS-induced CAR-T for MM treatment • Carisma shared its new myeloid cell-based platform, referred to as Engineered Microenvironment Converters (EM-C), for solid tumors Celltelligence provides insights: https://bit.ly/CT-867710

The Towards Degrader-Antibody Conjugates collection includes research and review articles on the preclinical to early clinical development of novel ADCs and protein degraders. Degrader-antibody conjugates are currently in preclinical development and represent the next frontier of antibody-conjugated therapeutics. Read the collection: https://bit.ly/3D6VOL8 #AACRchem24

Unlock innovation with Enamine! 🚀 Antibody–drug conjugates (ADCs) are a class of oncology therapeutics that provide targeted drug delivery by conjugation to a highly specific monoclonal antibody (mAb – synthetic antibodies derived from identical cells).  The design of linkers for ADCs is a challenge in terms of extracellular stability and intracellular release, and intracellular circumstances, such as the acid environment, the reducing environment and cathepsin, are considered as the catalysts to activate the triggers for initiating the cleavage of ADCs. Choosing suitable linkers can influence the stability, toxicity, PK properties, and pharmacodynamics of ADCs. 🛒 Please browse our website and take your drug discovery research to the next level! https://lnkd.in/gKveV84h

Our latest blog post is here to guide you step-by-step through your Kinase Inhibitor Development. From identifying targets to optimizing compounds, we've got you covered. Take your understanding of kinase drug discovery to the next level. Click the link below to access our comprehensive guide and elevate your expertise in the field. Let's accelerate your kinase inhibitor to the clinic together! 🔬💡 #biotech #drugdiscovery #kinaseinhibitors #oncology #pharma #innovation Step-by-Step Guide to Kinase Inhibitor Development - Reaction Biology 📚🔗 https://hubs.ly/Q02FNrGf0

DLA Piper advised Regor Pharmaceuticals (USA), a part of clinical-stage biotechnology company Regor Therapeutics Group, in the sale of its breast cancer cyclin-dependent kinase (CDK) inhibitors portfolio to Genentech, a member of the Roche Group, for US$850 million. The DLA Piper team was led by partners Adam Brenner and Jonathan Klein (both of New York). Read our press release: http://spr.ly/6047thEXb #Biotechnology #BreastCancer #CDK

DLA Piper advised Regor Pharmaceuticals (USA), a part of clinical-stage biotechnology company Regor Therapeutics Group, in the sale of its breast cancer cyclin-dependent kinase (CDK) inhibitors portfolio to Genentech, a member of the Roche Group, for US$850 million. The DLA Piper team was led by partners Adam Brenner and Jonathan Klein (both of New York). Read our press release: http://spr.ly/6047thEKS #Biotechnology #BreastCancer #CDK

🖼️ [POSTER] Promega's automated workflow for exosomal RNA isolation enables rapid, high-throughput miRNA extraction for RNA-seq and RT-qPCR, reducing processing time to under 2 minutes. ⬇️ Download the full poster to explore its potential for advancing exosome-based therapeutics: https://bit.ly/4efQYc7

DLA Piper advised Regor Pharmaceuticals (USA), a part of clinical-stage biotechnology company Regor Therapeutics Group, in the sale of its breast cancer cyclin-dependent kinase (CDK) inhibitors portfolio to Genentech, a member of the Roche Group, for US$850 million. The DLA Piper team was led by partners Adam Brenner and Jonathan Klein (both of New York). Read our press release: https://lnkd.in/dxiSZfNm #Biotechnology #BreastCancer #CDK